Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
651.47B
Market cap651.47B
Price-Earnings ratio
41.03
Price-Earnings ratio41.03
Dividend yield
1.95%
Dividend yield1.95%
Average volume
8.16M
Average volume8.16M
High today
$273.43
High today$273.43
Low today
$268.55
Low today$268.55
Open price
$269.51
Open price$269.51
Volume
11.92M
Volume11.92M
52 Week high
$290.25
52 Week high$290.25
52 Week low
$199.91
52 Week low$199.91

Stock Snapshot

With a market cap of 651.47B, Johnson & Johnson(JNJ) trades at $270.52. The stock has a price-to-earnings ratio of 41.03 and currently yields dividends of 1.95%.

On 2026-11-22, Johnson & Johnson(JNJ) stock traded between a low of $268.55 and a high of $273.43. Shares are currently priced at $270.52, which is +0.7% above the low and -1.1% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 11.92M, against a daily average of 8.16M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $290.25 and a 52-week low of $199.91.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $290.25 and a 52-week low of $199.91.

JNJ News

Seeking Alpha 15m
Notable healthcare headlines for the week: Health insurers, Pfizer, and J&J in focus

On the Move Notable healthcare headlines for the week: Health insurers, Pfizer, and J&J in focus Nov 22, 2026, 9:05 AM ET State Street Health Care Select Sector...

Notable healthcare headlines for the week: Health insurers, Pfizer, and J&J in focus
The Motley Fool 42m
Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

Free Article Explore Premium Services Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy? J&J is a healthcare giant...

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?
The Motley Fool 1h
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Free Article Explore Premium Services Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Johnson & Johnson's drug-and-device product...

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Analyst ratings

67%

of 27 ratings
Buy
66.7%
Hold
25.9%
Sell
7.4%

More JNJ News

NBC News 22h
Republican hopes fade for one last party-line bill before GOP loses majorities - NBC News

...

Republican hopes fade for one last party-line bill before GOP loses majorities - NBC News
Simply Wall St 2d
How Robot Surgery Launch At JNJ Has Changed Its Investment Story

Johnson & Johnson has completed the first commercial installation of its OTTAVA robotic surgical system at Memorial Hermann-Texas Medical Center and reported Ph...

How Robot Surgery Launch At JNJ Has Changed Its Investment Story
24/7 Wall St. 2d
These 4 Conservative Dow Jones Industrials Dividend Stocks Are Built for Sell-Offs

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

These 4 Conservative Dow Jones Industrials Dividend Stocks Are Built for Sell-Offs
Seeking Alpha 2d
Dividend Roundup: Nvidia, Disney, Merck, Johnson & Johnson and more

This week's dividend activity included increased payouts from Merck (MRK) and Walt Disney (DIS) as well as declarations from Nvidia (NVDA) and Nike (NKE). Addi...

Dividend Roundup: Nvidia, Disney, Merck, Johnson & Johnson and more
TipRanks 2d
Johnson & Johnson reports results from Phase 4 STAR study of TREMFYA

Johnson & Johnson announced late-breaking results from the Phase 4 STAR study of TREMFYA in biologic-naive adults with active psoriatic arthritis and axial invo...

TipRanks 2d
Johnson & Johnson price target raised to $300 from $285 at JPMorgan

JPMorgan raised the firm’s price target on Johnson & Johnson to $300 from $285 and keeps a Neutral rating on the shares as part of an analyst day preview. The c...

The Motley Fool 3d
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care

Free Article Explore Premium Services Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care Johnson & Johnson'...

Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.